相关实验视频

Updated: May 4, 2026

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

与酒精有关的肝硬化药理管理:有什么新鲜事?

Nipun Verma¹, Ashwin P Vinod¹, Ashwani K Singal^2,3,4

¹Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Expert opinion on pharmacotherapy

|October 3, 2024

概括

由于选择有限,酒精相关性肝病 (ALD) 需要新的治疗方法. 本综述探讨了ALD患者的新兴疗法和针对酒精使用障碍 (AUD) 的个性化方法.

科学领域:

肝病学肝病学是一种肝病学.
胃肠病学胃肠病学
成药物药物药物药物

背景情况:

酒精相关性肝病 (ALD) 影响了许多酒精使用障碍 (AUD) 患者,导致全球显著的死亡率和住院病例.
ALD通常在晚期呈现,如肝硬化或急性酒精相关肝炎 (AH),其短期死亡率高.
目前对ALD的治疗方法有限,仅对AH的葡萄皮质类药物有短期益处,需要新的治疗策略.

研究的目的:

审查和应用PIRO (倾向,损伤,反应,器官功能障碍) 概念,以了解ALD的进展.
突出治疗AUD在改善ALD患者长期结果方面的关键作用.
讨论ALD的新兴和个性化疗法.

主要方法:

应用PIRO概念到ALD的文献综述.
对ALD当前和新兴治疗策略的分析.
在ALD管理中讨论个性化医疗方法和肝移植.

主要成果:

该PIRO框架提供了一个全面的了解ALD作为一个持续的过程.
治疗AUD对于改善ALD的长期结果至关重要.
许多新型疗法,包括肠-肝-大脑轴调节器,干细胞和表观遗传调节器,对ALD治疗有希望.
肝移植是晚期ALD的绝对选择,越来越多的重点是选择的活跃饮酒患者的早期移植.

结论:

治疗ALD需要采取多方面的方法,包括解决AUD和探索创新的治疗方法.
针对特定患者资料和病原性途径的个性化治疗策略至关重要.
新兴疗法为改善ALD患者的疗效和治疗结果提供了显著的潜力.

关键词:

与酒精相关的肝脏疾病这是一个 PIRO 概念.酒精使用障碍饮酒障碍与酒精有关的肝炎.肝硬化是肝硬化的一种疾病.新兴的治疗方法.遗传和表观遗传因素系统性炎症系统性炎症

更多相关视频

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

相关概念视频

Esophageal Varices-I: Introduction

Esophageal Varices-I: Introduction

Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...

Esophageal Varices-II: Clinical Features and Management

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...